---
figid: PMC3693108__BMRI2013-130362.001
figtitle: Therapeutic molecular targets for endometrial cancer
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC3693108
filename: BMRI2013-130362.001.jpg
figlink: /pmc/articles/PMC3693108/figure/fig1/
number: F1
caption: Therapeutic molecular targets for endometrial cancer. Type I endometrial
  cancer (EC) frequently exhibits altered PI3K/PTEN/AKT/mTOR signal pathway, whereas
  type II EC frequently shows mutations in p53 and HER-2 overexpression. The upregulation
  of EGFR and VEGF, dysregulated microRNAs, and activation of cancer stem cell (CSC)/epithelial-mesenchymal
  transition (EMT) programs are involved in oncogenesis and progression of both cancer
  types. Currently, clinical trials assessing the efficacy of mTOR inhibitor, EGFR/HER2
  inhibitor, and antiangiogenic agent for EC have been conducted and demonstrated
  modest effects.
papertitle: Emerging Therapeutic Biomarkers in Endometrial Cancer.
reftext: Peixin Dong, et al. Biomed Res Int. 2013;2013:130362.
year: '2013'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9687718
figid_alias: PMC3693108__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC3693108__F1
ndex: 5403219d-decb-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3693108__BMRI2013-130362.001.html
  '@type': Dataset
  description: Therapeutic molecular targets for endometrial cancer. Type I endometrial
    cancer (EC) frequently exhibits altered PI3K/PTEN/AKT/mTOR signal pathway, whereas
    type II EC frequently shows mutations in p53 and HER-2 overexpression. The upregulation
    of EGFR and VEGF, dysregulated microRNAs, and activation of cancer stem cell (CSC)/epithelial-mesenchymal
    transition (EMT) programs are involved in oncogenesis and progression of both
    cancer types. Currently, clinical trials assessing the efficacy of mTOR inhibitor,
    EGFR/HER2 inhibitor, and antiangiogenic agent for EC have been conducted and demonstrated
    modest effects.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Erbb2
  - Egfr
  - Fgfr2
  - Vegfa
  - Kdr
  - Mtor
  - Pik3r1
  - ras
  - Hras
  - Kras
  - Rem1
  - Akt1
  - Mdk
  - Pten
  - Ephb2
  - Mapk1
  - Itk
  - Slc22a3
  - ERBB2
  - EGFR
  - FGFR2
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - KDR
  - FLT1
  - FLT4
  - MTOR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPKAP1
  - RICTOR
  - MLST8
  - PTEN
  - EPHB2
  - MAPK1
  - MAPK3
  - ITK
  - SLC22A3
  - Cancer
  - Lung cancer
---
